Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies

Seminars in Oncology

Volumn 42, Issue 3, 2015, Pages 495-505

  Bracarda, Sergio ^a   Altavilla, Amelia ^a   Hamzaj, Alketa ^a   Sisani, Michele ^a   Marrocolo, Francesca ^a   Del Buono, Sabrina ^a   Danielli, Riccardo ^b  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 MONOCLONAL ANTIBODY; GEMCITABINE; IMMUNOMODULATING AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 MONOCLONAL ANTIBODY; SUNITINIB; TICILIMUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; EXPERIMENTAL THERAPY; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; KIDNEY CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; KIDNEY NEOPLASMS; MALE; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY NEOPLASMS; MALE; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 84929150634     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.02.004     Document Type: Review

References (66)

1. A. Drakaki, and D.F. McDermott Novel Immunotherapies in GU malignancies Curr Oncol Rep 15 2013 224 231
2. K.S. Stafans, T.C. Bruno, A.K. Meeker, A.M. De Marzo, W.B. Isaacs, and C.G. Drake Human prostate infiltrating CD8+lymphocytes are oligoclonal and PD-1+ Prostate 69 2009 1694 1703
3. J. Matsuzaki, S. Gnatic, and P. Mhawech-Fauceglia Tumor-infiltrating NY-ESO-1 specific CD8+T cell are negatively regulated by LAG-3 amd PD-1 in human ovarian cancer Proc Natl Acad Sci U S A 107 2010 7875 7880
4. J. Fourcade, Z. Sun, and M. Benallaoua Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients J Exp Med 207 2010 2175 2186
5. P.H. Patel, R.S. Chaganti, and R.J. Motzer Targeted therapy for metastatic renal cell carcinoma Br J Cancer 94 2006 614 619
6. S.Z. Freed, J.P. Halperin, and M. Gordon Idiopathic regression of metastases from renal cell carcinoma J Urol 118 1977 538 542
7. J.B. deKernion, G. Sarna, R. Figlin, A. Lindner, and R.B. Smith The treatment of renal cell carcinoma with human leukocyte alpha-interferon J Urol 130 1983 1063 1066
8. S.A. Rosenberg, M.T. Lotze, and L.M. Muul Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer N Engl J Med 313 1985 1485 1492
9. S.A. Rosenberg, J.C. Yang, and S.L. Topalian Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 271 1994 907 913
10. U.S. Kammula, D.E. White, and S.A. Rosenberg Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer Cancer 83 1998 797 805
11. J.A. Klapper, S.G. Downey, and F.O. Smith High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006 Cancer 113 2008 293 301
12. B. Escudier, C. Porta, and M. Schmidinger Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 25 suppl 3 2014 iii49-56
13. L. Albiges, S. Oudard, and S. Negrier Complete remission with tyrosine kinase inhibitors in renal cell carcinoma J Clin Oncol 30 2012 482 487
14. J.C. Yang, M. Hughes, and U. Kammula Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J Immunother 30 2007 825 830
15. R.J. Greenwald, G.J. Freeman, and A.H. Sharpe The B7 family revisited Annu Rev Immunol 23 2004 515 548
16. R.H. Thompson, H. Dong, and C.M. Lohse PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma Clin Cancer Res 13 2007 1757 1761
17. G.J. Feeman, A.J. Long, and Y. Iwai Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
18. Y. Latchman, C.R. Wood, and T. Chernova PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 2001 261 268
19. L.L. Carter, L.A. Fouser, and J. Jussif PD-1: PD-L inhibitory pathway affects both CD4+and CD8+T cells and is overcome by IL-2 Eur J Immunol 32 2002 634 643
20. J.R. Brahmer, C.G. Drake, and I. Wollner Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
21. E.J. Lipson, W.H. Sharfman, and C.G. Drake Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody Clin Cancer Res 19 2013 462 468
22. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
23. C.G. Drake, D.F. McDermott, and M. Sznol Survival, safety, and response duration results of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up [abstract] J Clin Oncol (Meeting abstracts) 31 2013 4514
24. R.J. Motzer, B.I. Rini, and D.F. McDermott Nivolumab for metastatic renal cell carcinoma: Results of a randomized, dose-ranging phase II trial [abstract] J Clin Oncol (Meeting abstracts) 32 2014 5009
25. B.I. Rini, M. Stein, and P. Shannon Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma Cancer 117 2011 758 767
26. A. Amin, E.R. Plimack, and J.R. Infante Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma [abstract] J Clin Oncol (Meeting abstracts) 32 2014 5010
27. J.S. Ko, A.H. Zea, and B.I. Rini Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clin Cancer Res 15 2009 2148 2157
28. J.S. Ko, P. Rayman, and J. Ireland Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained Cancer Res 70 2010 3526 3536
29. H.J. Hammers, E.R. Plimack, and J.R. Infante Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma [abstract] J Clin Oncol (Meeting abstracts) 32 2014 4504
30. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1 a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1999 1365 1369
31. H. Dong, S.E. Strome, and D.R. Salomao Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
32. S.E. Strome, and L. Chen Costimulation-based immunotherapy for head and neck cancer Curr Treat Options Oncol 5 2004 27 33
33. H. Dong, and L. Chen B7-H1 pathway and its role in the evasion of tumor immunity J Mol Med 81 2003 281 287
34. S.E. Strome, H. Dong, and H. Tamura B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Res 63 2003 6501 6505
35. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci U S A 99 2002 12293 12297
36. R.H. Thompson, M.D. Gillett, and J.C. Cheville Costimulatory B7-H1 in renal cell carcinoma subjects: indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci U S A 101 2004 17174 17179
37. R.H. Thompson, W.S. Webster, and J.C. Cheville B7-H1 glycoprotein blocade: a novel strategy to enhance immunotherapy in subjects with renal cell carcinoma Urology 66 2005 10 14
38. R.H. Thompson, M.D. Gillett, and J.C. Cheville Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma Cancer 104 2005 2084 2091
39. R.S. Herbst, M.S. Gordon, and G.D. Fine A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors [abstract] J Clin Oncol (Meeting abstracts) 31 2013 3000
40. J.D. Powderly, H. Koeppen, and F.S. Hodi Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study [abstract] J Clin Oncol (Meeting abstracts) 31 2013 3001
41. D.C. Cho, J.A. Sosman, and M. Sznol Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) [abstract] J Clin Oncol (Meeting abstracts) 31 2013 4505
42. M. Callea, E.M. Genega, and M. Gupta PD-L1 expression in primary clear cell renal cell carcinomas (ccRCC) and their metastases [abstract] J Clin Oncol (Meeting abstracts) 32 2014 467
43. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
44. S. El Mir, and F. Triebel A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens J Immunol 164 2000 5583 5589
45. C. Brignone, B. Escudier, C. Grygar, M. Marcu, and F. Triebel A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma Clin Cancer Res 15 2000 6225 6231
46. E.J. Small, N.S. Tchekmedyian, B.I. Rini, L. Fong, I. Lowy, and J.P. Allison A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 2007 1810 1815
47. M.K. Tollefson, R.J. Karnes, and R.H. Thompson A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer [abstract] Genitourinary Cancer Symposium (Meeting Abstracts) 2010 168
48. E. Small, C. Higano, and N Tchekmedyian Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer [abstract] J Clin Oncol (Meeting Abstracts) 24 2006 4609
49. A.L. Harzstark, L. Fong, and V.K. Weinberg Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC) [abstract] J Clin Oncol (Meeting Abstracts) 28 2010 4689
50. L. Fong, S. Kwek, and S. O'Brien Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF Cancer Res 69 2009 609 615
51. W. Gerritsen, A.J. Van Den Eertwegh, and T. De Gruiji A dose-escalation trial of GM-CSF-gene transduced allogeneic with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC) [abstract] J Clin Oncol (Meeting Abstracts) 24 2006 2500
52. R.A. Madan, M. Mohebtash, and P.M. Arlen Overall survival (OS) analysis of a phase I trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mHRPC) [abstract] J Clin Oncol (Meeting Abstracts) 28 2010 2550
53. C. Jochems, J.A. Tucker, and K.Y. Tsang A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates Cancer Immunol Immunother 63 2014 407 418
54. T.M. Beer, S.F. Slovin, and C.S. Higano Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract] J Clin Oncol (Meeting abstracts) 26 2008 5004
55. S.F. Slovin, T.M. Beer, and C.S. Higano Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract] J Clin Oncol (Meeting abstracts) 27 2009 5138
56. Kwon Ed, C.G. Drake, and H.I. Sher Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomized, double blind, phase III trial Lancet Oncol 15 2014 700 712
57. C.G. Drake, A.D. Doody, and M.A. Mihlyo Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen Cancer Cell 7 2005 239 249
58. D.G. McNeel, H.A. Smith, and J.C. Eickhoff Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer Cancer Immunol Immunother 61 2012 1137 1147
59. J.A. Garcia, and R. Dreicer Systemic chemotherapy for advanced bladder cancer: updated and controversies J Clin Oncol 24 2006 5545 5551
60. A. Loskog, C. Ninalga, G. Paul-Wetterberg, M. de la Torre, P.U. Malmstrom, and T.H. Totterman Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines J Urol 177 2007 353 358
61. J. Nakanishi, Y. Wada, K. Matsumoto, M. Azuma, K. Kikuchi, and S. Ueda Overexpression of B7-H1 (PDL1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers Cancer Immunol Immunother 56 2007 1173 1182
62. B.A. Inman, T.J. Sebo, and X. Frigola PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression Cancer 109 2007 1499 1505
63. T. Powles, N.J. Vogelzang, and G.D. Fine Inhibition of PD-L1 by MPDL3280A leads to clinical activity in pts with metastatic urothelial bladder cancer (UBC) [abstract] J Clin Oncol (Meeting abstracts) 32 2014 5011
64. B. Carthon, J.D. Wolchok, and J. Yuan Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of presurgical clinical trial Clin Cancer Res 16 2010 2861 2871
65. S. Bracarda, M. Sisani, F. Marrocolo, A. Hamzaj, S. DelBuono, and A. Altavilla Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view Expert Rev Anticancer Ther 14 2014 1283 1294
66. J. Bellmunt, A. Orsola, J.J. Leow, T. Wiegel, M. De Santis, and A. Horwich Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 25 Suppl 3 2014 iii40-8